Filter posts

2013 Novel Drug Approvals

The FDA approved 24 novel drugs last year by our count, in line with average …

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Is 2014 a good time to invest in biotech? How many biotech IPOs will there …

Fewer Small Public Biotechs Today

A lot can happen in six years. The number of active biotech companies currently trading …

Biotech Stocks Hit Record Highs...Again

Biotech stocks hit an all-time high this week, driven by strong performance among large cap …

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

With 31 (and counting) life sciences companies having already placed IPOs on the market within …

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing …

China’s Biotech Innovators

As the Chinese government implements policies aimed at increasing innovation in the life sciences industry, …

The Return of the Biotech IPO

It isn’t just the volume of IPOs this summer that makes this window a victory …

Forecasted Sales Growth of Top Therapeutic Areas: Anti-Coagulants to Outpace

Although oncology has the largest market share in the therapeutics business, anti-coagulant products are expected …

R&D – Slow Growth Continues

According to a new report from EvaluatePharma, global pharmaceutical R&D had negative growth in 2012 …